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REVIEW
Abstract: Patient adherence to medication continues to be a cause of concern within the
medical profession. This review examines the various methods of quantifying the level of
patient adherence, progress in predicting causes of non-adherence, and the implications for
its management. Contributions from the medical, health belief, and psychosocial models are
discussed in order to highlight how the concept of adherence has changed over time. The
impact of epilepsy, seizures, and taking antiepileptic drugs (AEDs) on both adherence and
quality of life are also explored. The volume and quality of previous research conducted has
enabled a number of predictive factors to be identified, from which various strategies have
been developed. While this review concentrates on potential strategies in managing treatment
adherence within epilepsy, findings can equally be applied to other chronic conditions.
Keywords: adherence, compliance, antiepileptic drugs, epilepsy, QOL
Introduction
In assessing the effectiveness of prescribed medication there is a strong emphasis on
the ability of the patient to adhere to the regime recommended by the clinician (Trostle
1988; Donovan and Blake 1992). Various tools have been developed to measure
adherence but have limitations (Vermeire et al 2001). Most research has concentrated
on quantifying levels of compliance/adherence without first defining what is meant
by both terms (Vermeire et al 2001).
For individuals with epilepsy, adherence to medication is crucial in preventing or
minimizing seizures and their cumulative impact on everyday life. Non-adherence
to antiepileptic drugs (AEDs) can result in breakthrough seizures many months or
years after a previous episode and can have serious repercussions on an individual’s
perceived quality of life (Baker et al 1997).
Reasons for non-adherence are complex and multilayered (Donovan and Blake
1992; Mitchell et al 2000). Patients can accidentally fail to adhere through
forgetfulness, misunderstanding, or uncertainty about clinician’s recommendations,
or intentionally due to their own expectations of treatment, side-effects, and lifestyle
choice. There are various strategies suggested for managing patient adherence but
these are highly dependent on the reasons why a patient has not followed clinician
advice initially (Conrad 1985).
Terminology
Compliance
As Becker and Maiman (1975, p11) state “…patient non compliance has become the
best documented but least understood health related behaviour”. Donovan and Blake
(1992, p507) state how compliance is to “…obey, submit, defer or accede to
instructions”. Trostle (1988) describes how medical compliance can be seen as an
ideology with pre-conceived assumptions about the role of doctor and patient. The
relationship between the clinician and patient is one of unequal power dynamics
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with the traditional definitions of compliance constructed
within the medical model (Barofsky 1978).
While clinicians are the “gatekeepers” in providing
medication, the patient is the one who ultimately decides
whether they adhere to the recommended regime (Donovan
1992). The traditional medical model assumes that once the
medication regime is recommended by the clinician it is
then the responsibility of the patient to follow it; if patients
do not comply then the factors why need to be examined. In
other words the problem lies with the patient (Garrity
1981).
Social scientists have recognized how compliance is
rooted in this clinician perspective and have attempted to
examine the concept from a patient standpoint. The
medication regime recommended has to be interpreted by
the patient, who examines how the advice can be
incorporated into their lifestyle and “self regulates” their
drug taking schedule (Conrad 1985). A health belief model
hypothesized by Becker and Maiman (1975) (Figure 1)
includes the most frequently examined aspects of
compliance (age, drug regime, peer effects, doctor
relationship) interacting with an individual’s motivations,
and perceived benefits or costs of adherence to medication.
To Donovan and Blake (1992) this weighing up of severity
of symptoms and symptom relief juxtaposed against risks
of treatment illustrates how non-compliance can be
deliberate and the result of patients actively making
decisions about their own treatment.
Adherence
The gradual shift away from using the term compliance has
been encouraged due to the possibility of a patient somehow
being labeled as “deviant” for not following a recommended
drug regime (Conrad 1985). In contrast, adherence, while
not a perfect term (Barofsky [1978] describes it as what is
expected of the patient as opposed to compliance being told
what to do) at least implies a more mutual arrangement of
co-operation and agreement but is still prone to the same
difficulties in determining how it is measured. The concept
of both compliance and adherence is further complicated
when it is broadened to include general lifestyle changes
that have been recommended to promote optimum health
alongside a drug regime. Kobau and DiIorio (2003) in their
study found that patients who were adherent to their
medication schedule often failed to adapt their general
lifestyle (getting enough sleep, reducing alcohol intake,
avoiding stress) which could be just as detrimental to seizure
control and overall health.
Concordance
Recently the concept of concordance has been promoted as
a possible replacement to the notions of compliance or
adherence, advocating a decision-making process where
patients can feel more comfortable with their treatment
(Marinker and Shaw 2003). Crucially, the philosophy of
concordance has been embraced by the Department of
Health’s Task Force on Medicine Partnership whose
preliminary reviews feature contributions from both patients
and patient support groups such as the National Society for
Epilepsy (Carter et al 2005). The promotion of concordance
involves re-thinking the relationship between clinician and
patient, and this is likely to be a gradual process. While
there has been an emphasis on re-training the medical
profession, patients have been accustomed to working within
the compliance model and may themselves take some time
to adjust to the notion of concordance when they are
encouraged to make more decisions about their care (Bissell
et al 2004).
We will use the term adherence throughout this review
as while compliance implies a purely clinician’s perspective
we cannot assume that every patient-clinician interaction
has embraced the principles of concordance whereby the
patient’s decisions have had priority (Marinker and Shaw
2003). This is especially important when it is considered
that most research highlighted in this review pre-dates the
Department of Health’s decision to advocate the principles
of concordance or has been conducted outside the UK.
Adherence and concordance reflect a different process of
decision making about treatment and health outcomes but
ultimately, however, once treatment has been decided there
will still be a need to measure whether the treatment regime
has been effective both in terms of treating the condition
and the relative cost (Trostle 1988).
Similarly, there needs to be a distinction between
adherence and concordance in how they are measured.
Concordance suggests that the relationship between patient
and treatment provider is measured rather than direct health
outcomes (Bissell 2004). Research cited in this review has
measured outcomes in terms of levels of adherence to
medication; it is not clear to what extent patients have been
able to negotiate treatment decisions, particularly in the case
of clinical studies where patients have been asked to adhere
to a specific recommended regime.Neuropsychiatric Disease and Treatment 2007:3(1) 119
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Measuring adherence
Classification
Adherence research has involved the use of various criteria
in categorizing levels of adherence in patients. In a review
of adherence studies, Vermeire et al (2001) report that
adherence has largely been measured using process-
orientated definitions involving number of doses missed or
taken incorrectly rather than looking at the end result to
health. As Farmer (1999) in his review of adherence
measures states, the cut off point determining whether
someone is classed as adherent or not has an important role
in assessing drug effectiveness for clinical practice and
clinical trials. However, if the importance of adherence is
to ensure the best outcome for the patient it may be more
beneficial to measure it in terms of the level required for a
desirable end result for the individual (Vermiere et al 2001).
The adherence level to enable positive health outcomes
varies depending on the particular illness; for example, Read
et al (2003) report that to manage HIV a rate of 95% or
greater is needed continuously over a long period of time,
much higher than most chronic conditions.
How adherence is classified is highly dependent on the
method employed to measure it. Measuring adherence can
be divided into direct (blood levels, observation of drug
taking) and indirect methods (patient reporting through
questionnaires and diaries, pill counts, electronic
monitoring), and all have varying advantages over each other
(Osterberg and Blaschke 2005). Certain methods can
investigate only the consumption of medication over a
certain time but not how a particular regime was followed
(Farmer 1999).
Methods
Research into patient adherence has been undertaken
continuously from the 1970s. Various factors have been
identified as to why patients alter their medication-taking
behavior but an agreed definition or gold standard for
measurement remains elusive (Vermiere et al 2001).
Adherence has been measured in numerous ways including
drug plasma levels (Specht et al 2003), patient self reporting
either anonymously or reported to clinician (Cramer et al
2002; Doughty et al 2003), electronic monitoring (Cramer
et al 1989a, 1995), pill counting, and hair analysis (Williams
et al 1997). Each has important limitations with their
accuracy in assessing the level of adherence.
Measuring blood drug levels provides an objective
measurement of whether medication has been taken and
Figure 1 Model hypothesized by Becker and Maiman (1975) for predicting and explaining compliance behavior. Reprinted with permission from Becker MH, Maiman
LA. 1975. Sociobehavioural determinants of compliance with health and medical care recommendations. Med Care, 13:10-23. © 1975 Lippincott Williams & Wilkins.
Motivations
Concern about (salience of) health matters in 
general 
Willingness to seek and accept medical direction 
Intention to comply 
Positive health activities 
Value of Illness Threat Reduction
Subjective estimates of: 
  Susceptablity or resusceptibility (incl. 
  belief in diagnosis) 
  Vulnerability to illness in general 
  Extent of possible bodily harm* 
  Extent of possible interference with social 
 roles  * 
Presence of (or past experience with) symptoms 
Probability that compliant behaviour will reduce 
the threat
Subjective estimates of: 
  The proposed regimen’s safety 
  The proposed regimen’s efficacy to prevent, 
  delay or cure (incl. “faith in doctors and 
  medical care” and “chance of recovery”) 
Demographic (very young or old) 
Structural (cost, duration, complexity, side effects, 
  accessibility of regimen; need for new 
 patterns  of  behavior) 
Attitudes (satisfaction with visit, physician, other 
  staff, clinic procedures and facilities) 
Interaction (length, depth, continuity, mutuality of 
  expectation, quality and type of doctor-
  patient relationship; physician agreement 
  with patient; feedback to patient) 
Enabling (prior experience with action, illness or 
  regimen; source of advice and referral (incl. 
 social  pressure) 
Likelihood of:
Compliance with preventive 
health recommendations and 
prescribed regimens: e.g.
 screening,  immunizations, 
  prophylactic exams, drugs, 
  diet, exercise, personal and 
  work habits, follow-up tests, 
 referrals  and  follow-up 
  appointments, entering or 
  continuing a treatment 
 program. 
READINESS TO UNDERTAKE 
RECOMMENDED COMPLIANCE BEHAVIOUR 
MODIFYING AND ENABLING FACTORS  COMPLIANT
BEHAVIORS
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whether the level present is effective but is disadvantaged
by “white coat adherence” – a patient may be adhering to
the regime for only a day or two before an appointment
(Feinstein 1990). In the case of epilepsy, AED serum levels
can be obtained but this does not provide detailed
information about patient adherence over time and is valid
only for certain types of drugs which do not include many
of the so called “second generation” AEDs (Walters et al
2004). Despite this, medical personnel still request and rely
on these measures as an indicator of non-adherence (Walters
et al 2004).
Pill counting can be unreliable. Cramer et al (2002)
highlight that there are problems for patients to work out
whether they have taken the wrong number of tablets, as
counting the number of tablets left in a bottle and trying to
work out how many should be left is not always
straightforward (Cramer et al 2002). In a study by Paes et al
(1997), looking at electronic monitoring of oral antidiabetic
medication, patients were recorded as having problems with
taking too much medication on some days and then having
no medication at all in preceding or succeeding days. This
effect was more pronounced in the group of patients who
were taking once-daily doses of medication; this suggests
that patients could not always recall whether they had taken
their dose and highlights how pill counts would assume
adherence when the actual medication taking behavior posed
a significant risk to the individual’s health (Paes et al 1997).
Pharmacy records held on computerized systems are a
useful source of data when looking at adherence over larger
patient populations (Steiner and Prochazka 1997). The
expected time between prescription refills can be compared
to the rate at which a patient actually returns for more
medication. Christensen et al (1997) developed an algorithm
to calculate a patient’s adherence to antihypertensive drugs
based on computerized pharmacy records and found that
they were able to calculate adherence levels in 89% of 5500
prescriptions dispensed. Steiner and Prochazka (1997) state
that using pharmacy records measures the acquisition of
medication rather than consumption of medication and this
differentiates it from pill counting. However, like the pill
count method there needs to be an awareness of which facet
of adherence is being measured. The quantity of medication
acquired or assumed taken is only one aspect of adherence,
but the timing of medication can be equally critical (Choo
1999).
As Choo et al (1999) highlight, the method of measuring
adherence is dependent on how the variations in adherence
can affect health outcomes. Pharmacy records cannot be
used for some chronic conditions which involve frequent
changes of dose or for medications prescribed on a p.r.n.
basis and also cannot gauge the effectiveness of a drug
between dose intervals (Steiner and Prochazka 1997). The
recording of the medication regime in patient notes may
also not reflect the actual prescription details held on the
computer system. Christensen et al (1997) found that drug
name was correct, but that 14%–21% of the time the dosage
recorded was different and verbal instructions about dosage
were not mirrored in the prescription. These issues are of
particular relevance to adherence in epilepsy where it is quite
common for dosage to be changed and where incorrect
timing of doses can lead to inadequate drug levels potentially
causing a breakthrough seizure to occur (Specht et al 2003).
Patient reporting relies on the patients accurately
recalling when doses were missed and/or if they were taken
outside the recommended interval. The mechanisms of
patient self-reporting are also complex with a wide variety
of methods used including diaries, interviews, and
standardized interview techniques (Farmer 1999). Critical
to data collected using patient reporting is the approach used
by the interviewer or how questions are worded (Farmer
1999). The reality of the medication-taking routine followed
can differ widely from the patient’s reports. Buelow and
Smith (2004) compared patient reporting alongside data
collected from a Medication Event Monitoring System
(MEMS) cap which recorded the timing of when medication
was taken and found that patients who believed that they
managed their medication schedule effectively did not in
fact adhere completely to recommendations.
Use of MEMS (Medication Event Monitoring System)
devices answer many of the criticisms leveled at other
methods of measuring adherence. They allow adherence to
be more strictly defined by both number of pills missed and
intervals between doses. Electronic monitoring cannot
guarantee that medication was actually consumed but as
Cramer et al (1989a) suggest, a patient who has remembered
to open the bottle at the correct interval would be unlikely
to then not take the medication. Even this drawback of
assuming medication was taken has been addressed with
research into adherence to asthma medication with flow
sensors being incorporated into the device (Tashkin 1995).
Unfortunately, electronic monitoring can realistically be
used for only a limited time as it requires data to be
downloaded at regular intervals and the cost prohibits long-
term use (Osterberg and Blaschke 2005).Neuropsychiatric Disease and Treatment 2007:3(1) 121
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Adherence in epilepsy
Prevalence of epilepsy
While failing to adhere to treatment plans can adversely
affect individuals with any general medical condition, the
consequences of not taking medication can be more
immediate with epilepsy. Epilepsy as a chronic condition
relies heavily on adherence to medical advice in order to
maximize an individual’s quality of life by controlling
seizures more effectively while avoiding unwanted side-
effects (Baker et al 1997). Epilepsy also represents one of
the more common neurological conditions with an estimated
incidence of 4–10 people per 1000, with higher incidences
of epilepsy among infants and the elderly (Sander 2004).
Epilepsy Action estimate that epilepsy affects around 1 out
of every 131 people in the UK population.
Treatment
Of those diagnosed with epilepsy the vast majority are
treated with AEDs and approximately 70% can become
seizure-free once the most effective regime is followed
(Sander 2004). Monotherapy is viewed as the initial and
preferential option for treating epilepsy, the choice of drug
depending on seizure type and effectiveness of the drug
balanced against possible side-effects (Browne and Holmes
2004).
It is difficult to find estimates of how many people are
on monotherapy or polytherapy at any one point in time. A
US study of 314 adults found that 44% of patients were on
monotherapy with the remaining 56% of patients on
polytherapy (Yeager et al 2005). Similar proportions were
found in a European study assessing the quality of life of
over 5000 patients: 47% of patients were reported to be
receiving monotherapy, 36% were taking 2 AEDs (12% were
on 3, 1% 4 or more, and 4% were not receiving medication).
The drugs most commonly taken were carbamazepine
(53%), sodium valproate (33%), and phenytoin (25%)
(Baker et al 1997).
Investigating the extent of non-
adherence
It is generally believed that adherence rates with acute
conditions are much higher compared with chronic
conditions (Osterberg and Blaschke 2005). Adherence in
epilepsy has often been compared with other chronic
conditions such as asthma and diabetes due to their outward
manifestation of symptoms and the potential consequences
of non-adherence being very apparent compared with other
disorders which may have no symptoms or any immediate
consequences (Cramer et al 1989a). In the Claxton et al
(2001) review of 76 studies across various chronic medical
conditions the problem of adherence to drug regimes was
prevalent regardless of medical condition. Mean adherence
rates ranged from 51%–80% depending on drug regime and
how adherence was measured. As an example a prospective
study of asthma patients defined non-adherence as patients
taking less than 70% of doses over a specific time period or
who left out all doses for 1 week or longer, and even with
this criteria 51% were non adherent (Bosley et al 1995).
While chronic illness requires long-term medication
regimes and regular contact with the health system, due to
time and financial constraints it is often studied for only a
limited period of time, which has led to the call for longer-
term study using a combined methodology approach
(Casebeer and Verhoef 1997). The study of adherence to
medication with chronic conditions has been limited to short-
term monitoring of medication-taking which may not be
representative of actual behavior, and it has been shown
that even in the interval between appointments there is a
marked decline in adherence levels (Cramer 1990). The level
of adherence to AEDs also has to consider the length of
time a patient has been taking medication. In a study of 661
epilepsy patients, 71% had missed a dose at least once at
some point during their treatment but nearly half of the
overall sample had been taking AEDs for more than 10 years
(Cramer et al 2002).
Electronic monitoring of adherence has allowed
researchers to look at a patient’s AED medication-taking
behavior on a day-to-day basis. Cramer et al (1989a) defined
non-adherence in terms of omitting scheduled doses and
found that 76% of doses were taken as prescribed. There
was evidence of patients attempting to compensate for doses
missed by clustering doses, which meant that overall 92%
of tablets prescribed were taken but not at the specified
interval (Cramer et al 1989a). Fisher (2000) found that 20%
of respondents to their survey reported that they adjusted
medications on their own either by altering the dose or the
schedule. There are also differences in levels of adherence
across countries, with a recent study showing that 18%–
53% stated that they never missed their AED medication at
entry to the study (Doughty et al 2003).
Non-adherence to medication is not restricted to
involving taking too few doses or at the wrong time, patients
can also be judged as non-adherent by taking too large a
dose or too many tablets whether accidental or deliberate.
A survey of 2031 respondents who had epilepsy reportedNeuropsychiatric Disease and Treatment 2007:3(1) 122
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that 91% of patients never took more than the dose
prescribed but the remaining 9% did occasionally (Doughty
et al 2003). If patients’ perceptions of AED taking do differ
from reality this 9% may be an underestimate of what is
actually happening. The true extent of overconsumption may
be much higher, as individuals can accidentally take too
much medication by mistakenly thinking that they had
forgotten to take an earlier dose (Paes et al 1997).
Relationship between non-adherence
and seizures
Non-adherence to AED medication is not a modern
phenomenon. Trostle (1988) cites the example of a Dr
Gowers who, in 1881, reported on patients with epilepsy
admitted to hospital with recurrence of seizures due to
apparent non-adherence. The consequences of non-
adherence to AEDs can be immediate and devastating to an
individual’s quality of life (QOL). People with epilepsy are
acutely aware of the potential repercussions of not following
a drug regime. In a survey conducted in 2002 of 661 patients
with epilepsy 45% stated that they had a seizure when
missing a dose and only 32% of responders had informed
their doctor if they had missed any doses (Cramer et al 2002).
This is a worrying statistic, as it can give the false impression
that the drug regime is ineffective and persuade the clinician
to alter the management of medication unnecessarily
(Schroeder et al 2006). The other difficulty is that it has
been shown that patients do not always accurately remember
whether any doses were skipped, which can also lead the
clinician to believe that the drug regime needs to be altered
(Buelow and Smith 2004).
While non-adherence may cause a seizure to occur there
are many individuals who do not adhere to medication and
do not experience seizures and vice versa, as Shope et al
(1988) note this is a source of frustration to clinician and
patient alike. As mentioned previously, mistimed doses can
also be defined as non-adherence and can also result in a
seizure. Cramer et al (1995) reported how patients who
stayed up late would take a dose just before bedtime, which
may have been up to 15 hours since their previous dose by
which time drugs levels may have become ineffective in
preventing a seizure. Some patients who have not
experienced seizures for some time start to gradually reduce
their adherence to their medication, as they believe taking
it to be unnecessary, particularly if they have skipped doses
previously with no seizure occurring (Cramer et al 2002).
Gomes and Maia (1988) used questionnaires to ask
individuals with epilepsy a number of questions related to
medication-taking and reported that 61.4% of the group
agreed with a statement asking whether they reduced or
stopped medication to see what happened. Patients may not
perceive non-adherence as the main attributing factor in
seizures occurring. When patients were asked if anything
increased the likelihood of a seizure 41% mentioned stress/
emotion, 19% fatigue, and only 13% stated medication
missed (Hayden et al 1992). From a health economics
perspective non-adherence can also involve additional costs
to the health service due to the staff and resources required
to deal with admissions to hospital because of seizures or
seizure related injuries (Buck et al 1997b).
QOL and epilepsy
QOL adherence is prone to difficulties in establishing how
it is defined and measured. The World Health Organization
define it as an “…individual’s perception of their position
in life in the context of culture and value systems in which
they live and in relation to their goals, expectations,
standards and concerns” (WHO 1997). The WHOQOL
group have produced various tools designed to measure
QOL, which consist of key “domains” designed to assess
the impact of illness on health. Even with this definition
there is still debate about what these domains include and
how applicable they are across all illnesses or conditions
(Bowling 1995).
Gilliam et al (1997) asked patients with moderately
severe epilepsy to list any concerns with their epilepsy and
found a mean of 6.2 concerns were listed by each individual.
Driving, independence, and employment were the areas
listed most often and rated as the most important. While
seizures and treatment were also mentioned these domains
were not regarded as the main concerns by patients (Gilliam
et al 1997). There is limited opportunity here to explore all
the domains of QOL and how they are measured. However,
it is important to acknowledge that QOL depends on more
than seizure control and treatment. It has become
increasingly apparent that what an individual considers to
be a successful outcome goes beyond prevention of seizures
only (Sander 2005).
In managing QOL it is recognized that individuals with
epilepsy are a heterogeneous population. Patients who are
classed as refractory, for example, will report a greater
negative impact on their quality of everyday life compared
with those whose epilepsy is well controlled (Wheless 2006).
For the estimated 70% who become seizure free epilepsy
appears to impact less on their everyday life (Jacoby 1992)
and they may even have similar quality of life to theNeuropsychiatric Disease and Treatment 2007:3(1) 123
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population in general (Leidy et al 1999). Even in the absence
of seizures it is the unpredictability of epilepsy generally
that impacts on quality of life (Jacoby 2000). In a study
comparing quality of life of school children with epilepsy
and asthma (active and inactive) the epilepsy group were
affected more negatively than the asthma group regardless
of whether their epilepsy was active or not (Austin 1996).
The epilepsy group experienced greater social stigma over
a number of domains compared with both the inactive and
active asthma groups It could be feasibly concluded that
the nature of a seizure as opposed to an asthma attack
accounted for this difference (Austin 1996).
Seizures
Seizure frequency has been shown to be one of the main
factors involved in how a person with epilepsy perceives
their degree of stigma and their quality of health generally
(Baker et al 1997). In the European Quality of Life study,
51% of people with epilepsy experienced some level of
stigma but those with frequent seizures were three times
more likely to experience high levels of stigma and even
those having infrequent seizures experience more stigma
than those who were classed as seizure free (Baker et al
1997). Patients with tonic-clonic seizures alongside other
type of seizures are significantly more likely to feel
stigmatized (Ratsepp et al 2000). Individuals with
uncontrolled seizures in addition to the stigma experienced
are also less likely to be in employment or more likely to
encounter problems within their employment (Chaplin et al
1998). Seizures also have an impact on how the impact of
epilepsy is perceived. Sixty-three per cent of respondents
working part time or who were unemployed attributed this
to their epilepsy particularly if they were having frequent
seizures (Ratsepp et al 2000).
Injuries
Apart from seizures themselves, injuries that occur as a
consequence of having a seizure also have implications for
an individual’s health. Buck et al (1997a) reported on various
injuries that were common such as burns and scalds, and
revealed that 24% of the group had incurred head injuries
and a further 10% experienced dental injuries during the
previous year. A study surveying people with epilepsy
throughout Europe found similar proportions of injuries –
27% had experienced a head injury with 13% reporting
dental injuries (Baker et al 1997). Kirby and Sadler (1995)
recorded data from adult emergency rooms over a 1-year
period in Canada and reported that 15% of seizures resulted
in injury or death.
Antiepileptic drugs and side-effects
Unfortunately, AEDs have the potential to produce side-
effects singularly, and in combination with each other, as
well as interacting with other prescribed medication.
Common reported side-effects of AEDs include tiredness,
dizziness, weight gain or loss, acne, and rash along with
other less common but serious effects such as toxicity,
hepatic failure, and teratogenicity (Sander 2004; Perucca
and Meador 2005). The vast majority of patients will
experience at least one side-effect while being on AED
medication. Baker et al (1997) reported that only 12% of
patients involved in the European Study of Quality of Life
stated that they experienced no side-effects. Various side-
effects were reported including hair loss, weight gain,
trouble with teeth and gums, and problems with vision. Side-
effects relating to the central nervous system (CNS) such
as attention, memory, or concentration problems were also
reported in significant numbers (Baker et al 1997). The issue
of side-effects remains a fear for patients when following a
drug regime. Side-effects experienced by patients whether
actual or perceived increases the likelihood of non-
adherence (Buck et al 1997b).
Social impact of taking AEDs
The characteristics of side-effects experienced affect non-
adherence. Side-effects that are perceived to compromise
or interfere with an individual’s social skills discourage
adherence (Conrad 1985). Most AEDs have some CNS
associated side-effects which in turn are likely to affect an
individual’s psychosocial functioning (Buck et al 1997b).
Psychomotor processing, attention, and memory can all be
affected to varying degrees by AEDs (Perrucca and Meador
2005). This is of particular relevance to children and
adolescents who are striving for peer acceptance (Buck et
al 1997b). In a survey of 47 school children and adolescents,
half of the group felt embarrassed about their epilepsy and
a third felt excluded by peers (Anderson et al 2000). In
addition, taking AEDs was resented by half of the children
and sleepiness was reported as one of their main concerns
about taking the medication (Anderson et al 2000).
One further complication is the role of side-effects in
contributing towards accidental injury. Although seizures
can result in injury, experiencing side-effects might also be
a contributing factor in patients injuring themselves (Buck
et al 1997a). In a matched patient and control study, thoseNeuropsychiatric Disease and Treatment 2007:3(1) 124
Eatock and Baker
who reported injuries in the patient group mostly took two
or more drugs (van den Broek and Beghi 2004). Lawn et al
(2004) also found number of AEDs taken to be a risk factor.
However both Lawn et al (2004) and van den Broek and
Beghi (2004) conclude that while the relative risk of accident
or injury among people with epilepsy is high compared with
the general population, the risk is attributable mostly to
seizures and their frequency.
The actual physical act of having to take medication can
increase the levels of stigma experienced by the patient.
Taking AEDs reminds the individual that they have epilepsy
and they may resort to keeping pill-taking in public to a
minimum or disguise the purpose of the medication (Conrad
1985). Although patients may recognize the importance of
adherence in avoiding seizures and injuries, drug-taking
itself can be felt to be equally stigmatizing.
Factors affecting adherence
While the debate continues about the correct terminology
to use, research has continued to attempt to explain why
certain people show adherent behavior compared with
others, and different studies have attempted to identify
characteristics that can predict adherence (Buck et al 1997b;
Mitchell et al 2000; Kyngas 2001; Cramer et al 2002; Asadi-
Pooya 2005). Buck et al (1997b) identified various factors
indicative of those who were likely to show adherence (Table
1). As previously stated, these factors do not work in
isolation. Shope (1988) used the model hypothesized by
Becker and Maiman (1975) and found that while adherence
was affected by doctor–patient relationship, level of social
support, familiarity with drug regime, and age, the patients
who believed their treatment to be effective and those who
had more knowledge about their seizures and treatment, for
example, were more likely to show adherence.
Seizure type and frequency
As discussed previously, the quality of life for people with
epilepsy can differ according to seizure type and severity
but the effect on adherence is less clear. Specht et al (2003)
encouraged patients who had had seizures to come into
hospital in order to assess drug levels and found that out of
the non adherent group those with generalized tonic clonic
seizures appeared to show less adherence compared to other
seizure types. However, as Specht et al (2003) state, this
finding has to be interpreted with caution as people having
GTC seizures were more likely to see a clinician straight
after one occurring compared with other types of seizures.
Paradoxically, Shope et al (1988) found that self-reported
adherence among those adults whose seizures were well
controlled was higher than in those who classified
themselves as having a more severe seizure disorder,
whereas their pediatric research showed increased adherence
in the group who had more frequent seizures. Jones et al
(2006) have recently reported that in their group of patients
with epilepsy, a negative correlation could be detected
between seizure frequency and adherence. Gopinath et al
(2000) also found this in their study of 200 patients with
epilepsy.
AED regime
Throughout the research literature it has been concluded
that drugs taken less frequently daily is a significant aid to
adherence (Kruse et al 1991; Paes et al 1997; Claxton et al
2001; Cramer 2002). Frequency of dose seems to be an
important factor regardless of what the medication is for.
Kruse et al (1991), investigating adherence to fertility
medication, found that adherence was significantly
improved when the frequency was reduced from four times
daily to twice daily. With AEDs Cramer et al (2002)
calculated that the odds of missing a dose increased by 27%
each additional time a drug was expected to be taken daily.
This further supports the study of Cramer et al (1989a) using
a Medication Event Monitoring System (MEMS) over a total
period of 3428 days, which found that adherence rates
dropped considerably between those taking AEDs once daily
and four times daily (Table 2).
Doughty et al (2003) collected data from 2031 people
across Europe who were switched from sodium valproate
to depakine chrono. When questioned, 88% of patients at
baseline stated that they would prefer to take medication
once daily (89% 3 months later after the drug switch). Again,
differences in levels of adherence were affected according
to how many times a day medication was taken (Doughty
et al 2003). The possibility of only taking AED medication
once a day is an attractive proposition for patients who can
more easily fit this into their everyday routine and minimize
their chances of forgetting to take doses (Doughty et al
2003).
The number of different tablets to be taken daily is also
an important element in examining adherence rates. Buck
et al (1997b) noted a significant difference in adherence,
with those on polytherapy more likely to adhere. Cramer et
al (1995), in a study about dose frequency and adherence,
reported that the number of different medications to be taken
was not a factor affecting adherence, simply because if aNeuropsychiatric Disease and Treatment 2007:3(1) 125
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patient remembered they were due to take a dose they took
them all at the same time. Yeager et al (2005) analyzed
adherence by measuring the relative complexity of taking
AEDs. Everyday routine was affected by the guidelines in
taking medication, in particular whether they needed to be
taken alongside food or not. The nature of AED management
in introducing and withdrawing drugs also complicated the
drug regime, with some medication requiring an increase
over a set time period with another drug reducing in dose
over time (Yeager et al 2005).
Another adherence issue less frequently reported is
related to examining why patients sometimes take more
doses or higher doses than recommended. Patients can be
psychologically reliant on antiepileptic medication as a
method of reducing the amount of concern associated with
having seizures (Conrad 1985). For some patients, taking
AEDs may have been regarded as no longer necessary by
the clinician but patients fear the consequences should they
stop treatment, with a relapse having implications for
employment and overall quality of life (MRC AEDWS
Group 1992). Detailed interviews of people with epilepsy
have also revealed that patients take additional doses when
they feel that a seizure may be triggered, such as during
periods of stress or tiredness (Conrad 1985).
Table 1 Buck et al (1997b) factors affecting compliance with AED regimes
Reprinted with permission from Buck D, Jacoby A, Baker GA, et al. 1997b. Factors influencing compliance with antiepileptic drug regimes. Seizure, 6:87-93. © 1997
BEA Trading, Ltd.
Frequency miss taking AEDs: 
Never 
%
<once a month 
%
at least once a month 
%
Age: 
Under 60 (n = 460)  66 18    17  2 = 26.14 
60 or over (n = 180)  86    8    6  P < 0.00001
Teenager (n = 25)  52  32   16 
2 = 6.66 
Over 20 (n = 615)  72  14   14  P < 0.05 
How important to take drugs 
as prescribed: 
Very important (n = 597)  76  15   9 
2 = 100.50 
Fairly/not at all  P < 0.00001
 important  (n = 64)  29  17   53 
Reported feelings of stigma: 
Yes (n = 245)  66 19    15 
2 = 6.82 
No (n = 394)  74  13   13  P < 0.05 
No. of drugs 
Monotherapy (n = 467)  68 17    15 
2 = 13.61
Polytherapy (n = 190)  82  9   9  P < 0.01 
Side-effects due to AEDs: 
Yes (n = 326)  67 18    16 
2 = 9.6 
No (n = 328)  77  12   11  P < 0.01 
How perceive general 
practitioner: 
Easy to talk to (n = 394)  73 14    14 
2 = 6.58 
Not easy (n = 63)  57  24   19  P < 0.05 
Have regular arrangement 
to see GP about epilepsy: 
Yes (n = 69)  81  19*  2 = 4.61 
No (n = 382)  68  32  P < 0.05 
* Although there was no significant difference between never missing, missing less than once a month or missing 
at least once a month and having a regular arrangement to see GP, the difference was significant when the 
'frequency missed' variable was collapsed into two categories: whether missed at all or never missed. Neuropsychiatric Disease and Treatment 2007:3(1) 126
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Patient characteristics
Research examining adherence in individuals with any
chronic condition requiring medication has been analyzed
in terms of various characteristics such as socio-economic
background, age, and attitudes to medication-taking which
have similarly been investigated with epilepsy (for example
Buck et al 1997b; Britten 1994). While it appears that there
are no significant differences between genders, the age of
the patient is a factor, with adolescents considered less likely
to adhere (Cramer et al 1995; Buck et al 1997b; Anderson
et al 2000; Asadi-Pooya 2005).
Children and adolescents
Adherence levels for children and adolescents are highly
dependent on the level of support from parents. Kyngas
(2001) reports that this support was a strong predictor for
adherence in teenagers with epilepsy. From the first
diagnosis of epilepsy, family are encouraged to help by
monitoring seizures and medication and are involved in the
initial explanation of the importance of adherence (Schachter
1999). Shope (1988) looked at parent-reported adherence
compared with drug serum levels and reported that although
95% of parents believed medication prescribed reduced their
children’s seizures and 83% reported no problems in giving
medication to their children, the blood results showed that
only 57% had adhered to the drug regime.
Parents who had a good knowledge of seizures and
treatment and who sought out information about epilepsy
had a positive impact on their children’s adherence, but
surprisingly, parents who had higher expectations about their
children’s academic achievements showed less adherence
(Shope 1988). Austin et al (1996) investigated QOL in youth
with epilepsy and proposed that their poorer academic
progress compared with children with asthma could be due
to the neurological effects of epilepsy and/or the AED
medication which could negatively affect cognitive
functioning and therefore academic achievement as a result.
This might be a possible reason why parents may not
encourage their children to take medication as prescribed.
Other family influences beyond parents can also affect
adherence. While Asadi-Pooya (2005) reported that the
number of people in a family could negatively affect
adolescent adherence, Kyngas (2000) found no significant
effect. This might be explained by cultural difference –
Asadi-Pooya’s study was based in Iran and Kynga’s in Japan.
However, the nature of the family environment extends
beyond the number of people or who it comprises. Asadi-
Pooya (2005) noted that families with a positive history of
epilepsy were likely to adhere less to medication. Perhaps
surprisingly, teenagers and children from poorer families
and those who reported stressful life events were more likely
to adhere (Mitchell et al 2000). Mitchell et al (2000) also
found that families classified as being in a higher socio-
economic category were more likely to be non-adherent,
which lends weight to the theory that non-adherence can be
intentional rather than a reflection of difficulties in accessing
medical advice or an inability to understand (Mitchell et al
2000).
Teenagers with epilepsy appear to adhere less to
medication. Buck et al (1997b) reported how 52% of
teenagers reported that they never missed medication
compared with over 72% of over 20s. In scales used by
Kyngas (2000), only 37% were ranked as showing good
levels of adherence with medication. The reasons why
teenagers are less likely to adhere are complex. This age
group may feel increased levels of stigma associated with
taking AEDs (Buck et al 1997b), or may simply be at an
age when parental responsibility for ensuring adherence has
been relinquished to the adolescent who may simply forget
Table 2 Cramer et al (1989a,b) compliance rates for prescribed dosing regimes
Reprinted with permission from Cramer J, Mattson RH, Prevey ML, et al. 1989a. How often is medication taken as prescribed? A novel assessment technique. JAMA,
261:3273-7. © 1989 American Medical Association
Dosage*  No. of 
Patients
Mean No. of 
Days Observed 
Mean (SD) 
Compliance Rate, %†  Range, % 
   QD   3  191    87‡ (11)    73-99 
 BID  12 161    81§  (17)    44-100 
  TID   7  102    77§ (12)    52-90 
  QID   4      52    39   (24)     3-68 
 All  26 132    76   (21)     3-100 
*QD indicates once daily; BID, twice daily; TID, three times a day; and QID, four times a day. 
†P<.01 by analysis of variance. 
‡P<.01 vs QID group by Student's t test with Bonferroni multiple comparison correction.   
§P<.05 vs QID group by Student's t test with Bonferroni multiple comparison correction.  Neuropsychiatric Disease and Treatment 2007:3(1) 127
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to take the medication (Anderson et al 2000). Anderson et
al (2000) reported that 18 out of the 19 adolescents in their
study forgot to take medication at some point.
Adherence also depends on how taking medication
interferes with everyday life as viewed from the patient’s
perspective, despite simultaneously acknowledging the
importance of following the drug regime (Buck et al 1997b).
Younger people who believed that epilepsy was not affecting
social well-being were more adherent to medication.
Adolescents experiencing no perceived adverse effects on
their social well-being combined with parental support and
physician support, are factors believed to predict 97% of
those likely to show good adherence (Kyngas 2001).
Doctor–patient relationship
As noted earlier, an important aspect of the level to which
patients adhere is determined by their perception of their
relationship with the clinician. Patients’ decision-making
relies heavily on whether their expectations of the clinician
are met at each visit (Garrity 1981). It appears that successful
interactions with medical personnel can increase adherence.
Buck et al (1997b) highlighted how, while the number of
visits was unimportant, the patient feeling that they could
regularly talk to an understanding GP about epilepsy was a
key factor.
Gopinath et al (2000) investigated the patient perspective
of the doctor–patient relationship and found that both the
number of visits and effective communication between the
two promoted adherence. Kyngas (2001) studied 13- to 17-
year-olds with epilepsy and reported how 60% of the group
believed the physician to be interested in the epilepsy rather
than the individual and that medical personnel gave orders
rather than negotiating a care plan. However, as Gopinath
et al (2000) emphasize, in India and throughout the world,
physicians’ allocated time to consult with the patient has
become increasingly limited due to pressures on resources.
Psychosocial factors
Psychological factors such as anxiety or depression may
need to be investigated when adherence to medication is
poor. Bosley et al (1995) found that among their group of
individuals with asthma there was a significant relationship
between depression and the level of adherence. Attitudes
and perceptions about medication generally can influence
how likely it is for an individual to be adherent (Britten
1994). Britten conducted in-depth interviews with patients
and revealed that patients feared becoming dependent on
medication, worried about having to take it for life, and
some experienced a level of shame in having to take certain
medication.
Interwoven with all these factors of adherence is the
element of stigma. Stigma can adversely affect the ability
or perceived ability of a person to manage their epilepsy in
all aspects of self care (DiIorio et al 2003). The relationship
between stigma and management of epilepsy is complex.
In the DiIorio et al (2003) study high stigma levels were
associated with a number of socio-economic variables such
as unemployment, low income, and less education. High
levels were also associated with whether the seizures were
well controlled and if they had had a seizure in the previous
year (DiIorio et al 2003).
While there has been a focus on patient characteristics
in order to predict who is likely to be non-adherent, patient
characteristics are unable to provide a complete picture.
These contributing factors, while important, do not work in
isolation and a new approach may be to examine the
characteristics of situations which can trigger non-adherence
(Trostle 1988). There is already evidence available to show
how everyday environments such as school can affect
medication management (Anderson et al 2000). The
workplace is another situation which may hinder adherence.
The MRC Antiepileptic Drug Withdrawal Study noted that
a significant number of people who were still taking AEDs
felt that it affected work in some way (MRC AEDWS 1992).
Employer attitudes towards individuals with epilepsy may
also discourage the desire to inform them of their epilepsy
(Jacoby et al 2005). This is an important consideration for
people who need to take their medication at work.
Strategies
Previous proposed strategies have centered on improving
the effectiveness of communication between clinician and
patient. Opportunities for patients to discuss their epilepsy
treatment and any side-effects regularly with their GP
improve levels of adherence (Buck et al 1997b). A recent
Norwegian study using a nurse-led intervention program
over 2 years showed that adults with epilepsy benefited from
having regular opportunities to discuss their condition, and
showed marked improvements in QOL compared with the
group who were not in the intervention program (Helde et
al 2005). Interestingly, scores related to medication effects
showed a significant improvement in the intervention group
(Helde et al 2005). Having the opportunity to discuss any
fears of medication and possible side-effects could
potentially result in a greater level of adherence (Britten
1994).Neuropsychiatric Disease and Treatment 2007:3(1) 128
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For patients who are unclear about the importance of
following AED routines, various programs may be of benefit
particularly in cases involving children and adolescents
(Buck et al 1997b; Asadi-Pooya 2005). Educational
programs may be a method of improving adherence; patients
with more knowledge about seizures and treatment do
appear to show higher levels of adherence (Shope et al
1988). Gopinath et al (2000) take this one step further and
suggest wider dissemination of information about epilepsy,
lifestyle, and treatment through public education.
Decreasing the frequency of taking AEDs has been
shown to reduce the times patients forget to take medication
(Cramer et al 1995). Moreover the negative effects on social
relationships experienced by school-aged children can be
lessened if AEDs do not have to be taken during school
time (Anderson et al 2000). However, Paes et al (1997) did
not recommend this as a strategy in their study of diabetic
patients due to the possibility of a patient overconsuming
medication on one day and having no therapeutic coverage
on others. Adherence to timing of doses proves to be even
more critical in once-daily regimes, as variance in the time
medication is taken could result in 36 hours with no coverage
(Claxton et al 2001). Claxton et al (2001) recommend talking
to patients about the duration of action of individual drugs
and emphasize the importance of taking medication at
similar intervals.
Where appropriate, a switch to a sustained-release form
of an AED could allow a drug to be taken less frequently.
Research has shown that this results in fewer side-effects,
greater levels of adherence, and improvement in patient-
reported quality of life (Doughty et al 2003; Ficker et al
2005). The desire to minimize side-effects can be a factor
in explaining why patients omit medication or experiment
with the time interval of doses (Donovan and Blake 1992).
If drug regimes cannot be simplified further, blister
packs/pill organizers/multi-compartment medication devices
have been viewed as a possible method of improving
adherence. This may be of benefit for some individuals who
have difficulty remembering to take various medications
daily, but evidence of their effectiveness is limited and incurs
extra costs for the NHS (National Health Service – UK
publicly funded health service) (McGraw 2004).
More innovative ways of providing feedback to patients
about how they are managing their medication schedule
could be considered. As mentioned previously, blood level
monitoring shows recent doses taken prior to attending the
clinic, but a patient may have been omitting many doses
previously without this being apparent (Williams et al 1997).
Williams et al (1997) used hair analysis to show the
adherence pattern for carbamazepine over a period of 6
months, which highlighted any irregular dose taking during
over this time. This approach counteracts the drawbacks of
blood testing at clinic visits where only a snapshot of
adherence is possible.
Specht et al (2003) measured post-ictal serum levels of
AEDs to assess adherence and suggested that this provided
useful feedback to the clinician (in terms of possible
pharmacoresistance) and patient in explaining why a seizure
had occurred. Similarly, through use of a MEMS cap for a
short period of time patients could be presented with details
of inconsistencies in their drug regime (Cramer et al 2002).
Patients’ perceptions about how well they can self-
manage their own health (DiIorio et al 2003) and their
attitude to medication generally (Britten 1994) can and
should be discussed with clinicians. In some cases
psychosocial intervention and counseling may reduce the
level of stigma and encourage patients to feel more positive
about their ability to control their health (DiIorio et al 2003).
Enhancing self-efficacy has also been shown to make an
individual likely to engage in behaviors more beneficial in
minimizing the impact of epilepsy on everyday life (Kobau
and DiIorio 2003).
Finally, patients may be fully aware of the importance
of taking AED medication and the benefits gained by altering
their lifestyle choices in order to prevent seizures, but will
make a decision about the degree to which they follow
advice (Conrad 1985). As Conrad argues, patients only have
a small amount of time in contact with the clinician in their
“patient role”, after which they return to the practicalities
of their everyday routine where their adherence fluctuates
based on how they feel their medication affects their QOL.
Summary
Adherence to medication regardless of medical condition
remains an important problem in treatment. Factors that have
been discussed here – side-effects, drug regime, family
support, impact on everyday life, relationship with the
clinician – are unlikely to be the only predictors of
adherence. While adherence to treatment within the context
of epilepsy has been the focus of this review, these factors
can equally be applied to various chronic conditions.
Strategies to manage adherence originate from different
perspectives. While the medical model may advocate less
complex drug regimes, the use of measured pill containers,
and minimization of side-effects, the psychosocial model
analyzes non-adherence in terms of patient attitudes toNeuropsychiatric Disease and Treatment 2007:3(1) 129
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medication, stigma, family and peer influences, and ability
to manage self care. Neither model can adequately improve
adherence independently. Perhaps the best approach is to
offer a “menu” of adherence-enhancing strategies (Vermeire
et al 2001). However, what is increasingly clear from both
models is that total adherence is an unrealistic goal. The
emphasis has shifted away from total adherence towards a
compromise with both patient and clinician involved in a
joint process of treatment negotiation and decision-making
in order to achieve the best outcome for the individual.
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